PROS.U.TECH. NEW DLD (PROF)
XBER 
Summary
PROF Chart
Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Profound Medical Q2 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product shipments completed in July rather than June.
PROS.U.TECH. NEW DLD (PROF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PROS.U.TECH. NEW DLD ever had a stock split?
PROS.U.TECH. NEW DLD Profile
| XBER Exchange | CA Country |
Overview
Profound Medical Corp. is a commercial-stage medical device company that focuses on developing magnetic resonance guided ablation procedures. These revolutionary procedures are designed for treating various conditions such as prostate disease, uterine fibroids, and providing palliative pain treatment. The company has a global presence with operations in Canada, Germany, the United States, and Finland. With its headquarters located in Mississauga, Canada, Profound Medical Corp. leverages state-of-the-art technology to improve patient care in hospitals and treatment facilities worldwide.
Products and Services
- TULSA-PRO System: This innovative system works seamlessly with magnetic resonance imaging (MRI) scanners to provide a highly precise treatment option for prostate disease. It is designed to deliver targeted therapy with minimal invasiveness, aiming to reduce side effects and improve recovery times for patients. The TULSA-PRO system underscores Profound Medical Corp.’s commitment to advancing prostate disease treatment through technology.
- Sonalleve: Sonalleve is a versatile therapeutic platform that offers non-invasive treatment solutions for uterine fibroids and palliative pain relief for patients suffering from bone metastases. The technology behind Sonalleve uses high-intensity focused ultrasound (HIFU) to target and treat the affected areas without the need for surgical intervention. This platform demonstrates the company’s dedication to providing innovative and patient-centric treatments for complex health issues.
Contact Information
